News and Announcements
CVC Add+Venture Fund on Track for a First Close of $10m in August
- Published August 03, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Capital raising for the CVC Add+Venture Fund is progressing well and based on applications already received we are on track for a first close of $10m this month (August).
We continue to assess great quality deal flow including a medical compliance and safety technology company with existing revenues, a platform for rapid web and app development, multiple cybersecurity opportunities, as well as a disruptive online B2C marketplace. The Add+Venture team is looking forward to closing the capital raise and turning our deal flow into investments in the Fund.
ABOUT CVC ADD+VENTURE FUND
The CVC Add+Venture Fund is a venture capital fund launched by CVC Limited, an ASX listed investment management company in operation since 1985, with net assets of over A$200 million. The Fund provides investors with tax effective access to the potentially outsized returns available from investing in early and expansion stage companies, utilising the experienced CVC Investment Team who have delivered returns in excess of 25% p.a. from CVC’s earlier stage portfolio over the past 5 years.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
